TX-DENTALMONITORING
4.10.2021 16:09:05 CEST | Business Wire | Press release
DentalMonitoring, the company that pioneered artificial intelligence in dental and orthodontic care, is thrilled to announce the launch of the ScanBoxpro .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005610/en/
Built upon the success of their previous DM ScanBox, their latest FDA-registered innovation is a portable device patients can take with them for precise AI-powered scans anywhere and anytime. This hardware accompanies the flagship software solution DentalMonitoring, a customizable cloud-based platform for remote clinical monitoring of orthodontic treatments designed to create a single automated workflow per patient and boost practice scalability.
The device consists of two components — a cheek retractor tube designed to draw the cheeks and lips from the buccal and labial surfaces of the teeth and gums during scanning and a phone holder designed to accommodate a smartphone.
Paired with the unique DM app for patients, the ScanBoxpro offers:
- Consistent imaging over time for precise tracking of treatment progress including aligners, braces and retainers of all brands
- Excellent occlusal and lateral views, including molar occlusion
- Increased portability
- Suited for all patients from 6 years old.
- Easy storage capability with 41% less volume
- Autoclavable capacity
“We couldn’t be prouder to introduce our latest innovation as we continue to go further and break new ground with our solutions,” says Phillipe Salah, CEO of DentalMonitoring. “The ScanBoxpro is a game-changer for patients. It’s lightweight, portable and can easily join them on-the-go, anywhere, for high-quality scans powered by the first and most robust AI in the industry. In turn, it allows doctors to have control at every stage of treatment and helps automate their workflow while enhancing their patient experiences.”
The ScanBoxpro is the newest addition to DentalMonitoring’s family of devices and software solutions including SmileMate, for engagement, triage and patient conversion and DentalMonitoring, the only available AI-based remote monitoring solution available to both fixed and removable orthodontic appliances of all brands.
About DentalMonitoring
DentalMonitoring was started with a simple idea: oral care should be connected and continuous — even outside the practice. Since then, the company has developed cutting edge algorithms based on the industry's largest image database that perform high-level AI analysis, calculate tooth movement remotely, and create photo-realistic simulations.
Their suite of solutions is a fully scalable, AI-powered platform giving providers the insights needed to modernize dental care. Backed by the industry’s largest AI database, the platform and patented technology allows doctors to detect and monitor oral observations remotely, optimizing in-person appointments. Smarter remote care breaks barriers to treatment for patients, and practices can broaden their presence with smarter care.
More information: www.dental-monitoring.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005610/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom